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ABSTRACT
Patients surviving with a stroke have an increased risk for recurrent stroke. Clopidogrel is 
widely used to prevent recurrent stroke. However, clopidogrel may cause gastrointestinal 
bleeding (GIB). Therefore, proton pump inhibitors (PPIs) are recommended to reduce 
the side effect of clopidogrel. Unfortunately, these both drugs are metabolized in the 
liver by the same enzyme i.e. cytochrome P4502C19 (CYP219) that may reduce the 
effect of clopidogrel. The aim of this study was to evaluate the influence of PPIs on the 
effect of clopidogrel in the prevention of recurrent stroke. It was a hospital-based case 
control study conducted in Bethesda Private Hospital, Yogyakarta involving 392 patients 
with recurrent stroke as cases and 784 patients with first-ever stroke as controls. The 
exposure of PPIs during clopidogrel therapy on both cases and controls groups were 
recorded from prescription records for at least six months before index date. The duration 
of PPIs exposure were categorized as current expoure (less than two months before 
the index date) and recent exposure (2-6 months before the index date). The result 
showed there was no influence of PPIs exposure on the effect of clopidogrel on the risk 
of recurrent ischemic stroke (OR: 1.00; 95% CI: 0.56-1.79). Moreover, the current use of 
PPIs and clopidogrel could decrease the risk of recurrent ischemic stroke (OR: 0.04; 95% 
CI: 0.01-0.41). In conclusion, there is no association between PPI exposure and the risk 
of recurrent stroke in patients receiving clopidogrel. 
ABSTRAK
Penderita strok mempunyai risiko stroke berulang lebih tinggi. Klopidogrel digunakan 
secara luas untuk mencegah stroke berulang. Namun demikian klopidogrel kemungkinan 
menyebabkan pendarahan gastrointestinal. Oleh karena itu penghambat pompa proton 
(PPP) dianjurkan diberikan untuk mengurangi risiko efek samping klopidogrel. Sayangnya 
kedua obat ini dimetabolisme di hepar oleh enzim yang sama (CYP2C19) yang kemungkinan 
dapat menurunkan efek klopidogrel. Tujuan penelitian ini adalah mengkaji pengaruh 
pemberian PPP terhadap efek klopidogrel dalam mencegah stroke berulang. Penelitian ini 
merupakan penelitian kasus control berbasis rumah sakit yang dilakukan di Rumah Sakit 
Bethesda, Yogyakarta. Sebanyak 392 pasien yang mengalami stroke berulang sebagai 
kasus dan 784 pasien yang pertama kali menderita stroke sebagai control. Pemberian 
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PPP selama pengobatan dengan klopidogrel pada kedua kelompok diambil dari catatan 
peresepan sejak enam bulan terakhir mulai dari tanggal kedatangan. Pemberian PPP 
dikelompokan dalam dua kelompok yaitu pemberian <2 bulan dan antara 2-6 bulan 
sejak tanggal kedatangan. Hasil penelitian menunjukkan tidak ada pengaruh pemberian 
PPP terhadap efek klopidogrel pada risiko terjadinya stroke berulang (OR: 1,00; 95% CI: 
0,56-1,79). Selain itu, pemberian PPP dan klopidogrel <2 bulan sejak kedatangan dapat 
menurunkan risiko stroke berulang (OR: 0,04; 95% CI: 0,01-0,41). Dapat disimpulkan 
tidak ada hubungan antara pemberian PPP dan risiko stroke berulang pada pasien yang 
menerima klopidogrel.     
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INTRODUCTION
Stroke is a common form of cardiovascular 
disease affecting the blood supply to the 
brain. Stroke is one of the leading causes 
of morbidity and mortality worldwide.1 Of 
the approximately 16.9 million strokes that 
occur annually, over 80% are ischemic stroke. 
Nearly six million die and another five million 
are left permanently disabled annually.2-4 In 
Indonesia, Stroke is the first leading cause 
of death and its prevalence is 7.0 per 1000 
population.5 Data launched by Bethesda 
Private Hospital, Yogyakarta showed that 
800-1000 cases of stroke has been reported 
annually. 
Patients surviving with a stroke or transient 
ischemic attack (TIA) have an increased 
risk for recurrent stroke. Without secondary 
prevention, the risk for recurrent stroke is 30-
40% among patients with stroke during 5st 
year after the primary event. Whereas among 
patients with TIA, the risk for recurrent stroke 
is 8-12% after seven days post TIA and more 
than 20% among the another groups of patients 
with stroke.6  Therefore, secondary prevention 
has been strongly recommended to reduce the 
risk for recurrent stroke.7,8
Clopidogrel is a thienopyridine-class 
antiplatelet agent that acts by inhibits platelet 
activation induced by adenosine diphosphate 
(ADP).7 Clopidogrel is widely used to prevent 
recurrent stroke. Clopidogrel alone or in 
combination with aspirin has successfully 
proved its benefit in the prevention the recurrent 
stroke.7,9,10 However, the use of clopidogrel 
is often associated with an increased risk of 
upper gastrointestinal bleeding (UGIB).10,11 
To reduce the risk of UGIB, clopidogrel is 
recommended in combination with proton 
pump inhbitors (PPIs) to prevent the recurrent 
stroke.7,12
Clopidogrel is a prodrug that must be 
metabolized in the liver mainly by cytochrome 
P-4502C19 isoenzymes (CYP2C19) to 
generate an active metabolite. Moreover, 
CYP2C19 is also involved in the metabolisms 
of PPIs. Therefore, the interaction between 
clopidogrel and PPIs may be occurred in the 
concomitant use of these drugs. However, 
previous studies showed that the interaction 
between clopidogrel and PPIs have not 
been clearly proven. It was reported that 
omeprazole would reduce the antiplatelet 
effect of clopidogrel lead to increase the 
risk of stroke, death, myocardial infarction 
and unstable angina.13-17 In contrast, other 
studies showed no association between co-
administration of PPIs in patients receiving 
clopidogrel with the risk of cardiovascular 
adverse events including recurrent stroke.18-20 
This study was conducted to prove the effect 
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of PPIs on recurrent stroke in patients treated 
with clopidogrel following ischemic stroke. 
MATERIALS AND METHODS 
Subjects
The study was a hospital-based case 
control study conducted in Bethesda Private 
Hospital, Yogyakarta involving patients 
surviving with an ischemic stroke aged 18-65 
years who were discharged from the hospital 
between December 2011 and June 2012. The 
study was approved by the Medical and Health 
Research Ethics Committee of Universitas 
Gadjah Mada, Yogyakarta.
    
Procedures
Data of stroke patients were collected 
from medical record of patients including 
stroke registry and inpatient book registry at 
Bethesda Private Hospital, Yogyakarta. Based 
on medical record from Medical Record 
Installation at the hospital, the ischemic stroke 
patients were then classified into patients with 
recurrent stroke and patients with first-ever 
stroke. The patients with recurrent stroke 
were defined as cases with the inclusion 
criteria were as follows: 1) all patients with 
recurrent stroke during 5st year after the 
primary event; 2) aged more than 18 years. 
The exclusion criteria of the cases were as 
follows: 1) having a not complete medical 
record; 2) having an history of  liver and 
renal diseases in the last six months until the 
onset of recurrent ischemic stroke observed; 
3) suffering a gastroesophageal reflux disease 
and peptic ulcers. The patients with first-
ever stroke were defined as control with the 
inclusion criteria were as follows: 1) patients 
with first-ever stroke and were controlling in 
outpatient polyclinic; 2) aged more than 18 
years. The exclusion criteria of the control 
were as follows: 1) having a not complete 
medical record; 2) having an history of liver 
and renal diseases in the last six months until 
visiting at outpatient polyclinic; 3) suffering 
a gastroesophageal reflux disease and peptic 
ulcers. The study was designed to have 2:1 
matching, with two controls for each cases. 
The matching criteria were gender, age (born 
within 5 years) and index date (within 2 weeks). 
The exposure of PPIs during clopidogrel 
therapy on both cases and controls groups 
were recorded from prescription records for at 
least 6 months before index date. The types 
of PPIs administered including  omeprazole, 
esomeprazole, lansoprazole and pantoprazole 
were recorded. The duration of PPIs exposure 
was categorized as current exposure (less than 
2 months before the index date) and recent 
exposure (2-6 months before the index date).
Statistical analysis
Conditional logistic regression analysis 
was used to estimate the odds ratio (OR) for 
the association between recurrent stroke and 
exposure to a PPI, using as the reference 
group of patients with no prescription for a 
PPI. The factors which may interfere with the 
outcome including history of diabetes, blood 
pressure, lipid profile, Charlson comorbidity 
index, and the drugs use as a co-medication 
for the patients, such as statin, antiplatelet 
(low dose ASA), diuretics, ACE inhibitors, 
angiotensin receptor blockers, CYP inducers, 
CYP inhibitors, calcium channel blockers 
and β-blockers were adjusted. The data 
obtained were analyzed using Chi square 
test for bivariate and logistic regression for 
multivariate using a statistic software. 
RESULTS 
Over the 18-months study period, 1,479 
patients surviving with an ischemic stroke 
aged 45 years or older were identified. The 
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patients were selected using consecutive 
method in order to classify into cases and 
controls groups. A total 392 patients with 
recurrent stroke as cases and 784 patients with 
first-ever stroke as controls were identified 
and recruited in this study. The characteristics 
of cases and controls are presented in TABLE 
1. The characteristics of cases were likely 
similar in term of gender and sex. However, 
the cases were more likely to have a history 
of hypertension and dibetes mellitus. The 
significant difference in mediations use 
between cases and controls especially for 
ACE inhibitors, ARB, β-blockers, Ca channel 
blockers, statin, CYP inducers, CYP ihibitors 
and low dose ASA were observed in this 
study (p<0.05). Moreover, the Charlson 
index between cases and controls was also 
significantly different (p<0.05). 
Variables Cases(n=392)
Controls
(n=784) p
Sex 
•	 Male 229 (58.4%) 458 (58.4%)
1.000
•	 Female 163 (41.6%) 326 (41.6%)
Age (year) 
•	 75 yo 62 (15.8%) 119 (15.2%)
0.163
•	 60-74 yo 185 (47.2%) 327 (41.2%)
•	 45-59 yo 131 (33.4%) 295 (37.6%)
•	 < 45 14 (3.6%) 43 (5.5%)
Blood pressure
•	 Hypertension 159 (40.6%) 159 (20.3%)
<0.001
•	 Normal 233 (59.4%) 625 (79.7%)
Glycemic index
•	 Uncontrolled DM 104 (26.5%) 165 (21.0%)
0.001
•	 Controlled DM 26 (6.6%) 35 (4.5%)
•	 Normoglycemia 241 (61.5%) 565 (72.1%)
•	 No info 21 (5.4%) 19 (2.4%)
Lipid profile
•	 Dyslipidemia 221 (56.4%) 492 (62.8%)
0.080•	 Non dyslipidemia 140 (35.7%) 247 (31.5%)
•	 No info 31 (7.9%) 45  (5.7%)
ACE inhibitor
•	 No 335 (85.5%) 717 (91.5%)
0.002
•	 Yes 57 (14.5%) 67 (8.5%)
ARB
•	 No 331 (84.4%) 608 (77.6%)
0.006•	 Yes 61 (15.6%) 176 (22.4%)
β-blocker
•	 No 379 (96.7%) 774 (98.7%)
0.017
•	 Yes 13 (3.3%) 10 (1.3%)
TABLE 1. Characteristics of subjects of cases and controls
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Ca channel blocker
•	 No 292 (74.5%) 538 (68.6%)
0.037
•	 Yes 100 (25.5%) 246 (31.4%)
Diuretic
•	 No 366  (93.4%) 712 (90.8%)
0.136
•	 Yes 26 (6.6%) 72 (9.2%)
Statin 
•	 No 317 (80.9%) 466 (59.4%)
<0.001
•	 Yes 75  (19.1%) 318 (40.6%)
OAD
•	 No 308 (78.6%) 614 (78.3%)
0.920
•	 Yes 84 (21.4%) 170 (21.7%)
CYP inducer
•	 Yes 43 (11.0%) 116 (14.8%)
0.070
•	 No 349 (89.0%) 668 (85.2%)
CYP inhibitor
•	 Yes 81 (20.7%) 328 (41.8%)
<0.001
•	 No 311 (79.3%) 456 (58.2%)
Low dose ASA
•	 No 218 (55.6%) 146 (18.6%)
<0.001
•	 Yes 174 (44.4%) 638 (81.4%)
Charlson index
•	 ≥2 165 (42.1%) 262 (33.4%)
0.004
•	 <2 227 (57.9%) 522 (66.6%)
ACE inhibitor: angiotensin converting enzyme inhibitor; ARB: angiotensin receptor 
blocker; OAD: oral antidiabetic;  CYP inducer: cytochrome P-450 2C19 inducers; 
CYP inhibitor: cytochrome P-450 2C19 inhibitors; ASA: acetylsalicylic acid 
No influence of PPIs exposure on the effect 
of clopidogrel on the risk of recurrent ischemic 
stroke was observed in this study (OR: 1.00; 
95% CI: 0.56-1.79) (TABLE 2). Furthermore, 
sub group analysis to the patients receiving 
clopidogrel also showed no influence of PPIs 
exposure on the risk of recurrent stroke (OR: 
1.35; 95% CI: 0.61-2.96) (TABLE 3).
Exposure
Recurrent stroke
p OR (95%CI)
Cases Controls
(n=392) (n=784)
With PPI  18 (4.6%) 36 (4.6%)
1.000
1.00 (0.56-1.79)
Without PPI 374 (95.4%) 748 (95.4%) Reference
Total 392 (100.0%) 784 (100.0%)
TABLE 2. Risk factor of PPIs and clopidogrel exposures on the risk of recurrent 
ischemic stroke
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Exposure
Stroke
p
Unadjusted OR
(95%CI)
Adjusted OR*
(95%CI)
Recurrent Not recurrent
n % n %
With PPI 18 24.3 36 12.6
0.12
2.22 (1.18-4.19) 1.35 (0.61-2.96)
Without PPI 56 75.7 249 87.4 Reference
Total 74 100.0 285 100.0
  *   Adjusted for age, gender, blood pressure, history of diabetes,  use of ACE inhibitors,  ARB, β-blockers, 
Ca channel blockers, diuretics, statin, OAD, CYP induers, CYP inibitors, low dose ASA and Charlson 
index.
TABLE 3.  Influence of PPIs exposure to the patients receiving clopidogrel therapy on the 
risk of recurrent ischemic stroke
Whereas subgroup analysis to the durati-
on PPIs exposure showed that the current 
exposure of PPIs could reduce the risk of 
recurrent stroke OR 0.04 (95% CI 0.01 to 
0.41).
PPI Exposure
Stroke
p
Unadjusted OR
(95%CI)
Recurrent Not recurrent
n % n %
Current PPI 11 61.1 35 97.2 0.001 0.04 (0.01-0.41)
Recent PPI 7 38.9 1 2.8 Reference
Total 18 100.0 36 100.0
TABLE 4. Risk factor of duration of PPIs exposure on the risk of recurrent ischemic stroke
In this study, omeprazole was the most 
common type of PPIs used in combination 
with clopidogrel on patients surviving stroke 
at Bethesda Private Hospital. Moreover, 
omeprazole (OR: 0.04; 95% CI: 0.01-0.41) 
could reduce the risk of recurrent stroke more 
better than esomeprazole (TABLE 5).
PPIs
Stroke
p OR (95% CI)Cases Controls
n % n %
Omeprazole 10 55.6 22 61.0 0.461 0.46 (0.56-3.70)
Lansoprazole 6 33.3 11 30.6 0.589 0.54 (0.06-4.91)
Pantoprazole 0 0 1 2.8 0.361 -
Esomeprazole 2 11.1 2 5.6 Ref
Total 18 100.0 36 100.0
TABLE 5. The effect of PPI types on the risk of recurrent stroke
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DISCUSSION 
In this hospital-based study, PPI exposure 
to the ischemic stroke patients did not 
influence the effect of clopidogrel on the risk of 
recurrent ischemic stroke event. The influence 
of PPI on the effect of clopidogrel on stroke 
patients has been reported by some authors 
with different results. Some authors reported 
that PPIs exposure might influence the effect 
of clopidogrel, whereas other authors might 
not influence. 
O’Donoghue et al.17 reported that there is 
no association between the PPI use and risk 
of cardiovascular adverse events in patients 
receiving clopidogrel (adjusted hazard ratio/
HR: 0.94; 95% CI: 0.80–1.11).  In addition, 
Bhatt et al.18 also reported that there is no 
association between the omeprazole use and 
the risk of cardiovascular events in patients 
receiving clopidogrel (HR: 1.02; 95% CI: 
0.70-1.51). No association between PPIs use 
and a significantly increased risk of recurrent 
stroke (adjusted odds ratio/AOR: 1.05; 95% 
CI: 0.60 - 1.82) or death (AOR: 1.84; 95% 
CI: 0.88-3.89) was also reported among older 
patients treated with clopidogrel after stroke.19 
Different results concerning the influence 
of PPI on the effect of clopidogrel have been 
also reported by some authors. Gilard et 
al.12 reported that omeprazole significantly 
decreased the effect of clopidogrel on platelet. 
Furthermore, Juurlink et al.13 reported that 
current use of PPIs was associated with an 
increased risk of reinfarction (adjusted OR: 
1.27; 95% CI: 1.03-1.57). It was also reported 
that concomitant use of clopidogrel and PPI 
after hospital discharge for acute coronary 
syndrome was associated with an increased 
risk of adverse outcomes.14,15 In addition, 
concomitant use of a PPI and clopidogrel 
compared with clopidogrel alone was 
associated with a higher rate of major adverse 
cardiovascular events within 1 year after 
coronary stent placement.16
Both clopidogrel and PPIs are metabolized 
in the liver by CYP2C19.  Therefore, the 
potential interaction between clopidogrel 
and PPIs may be occurred in the concomitant 
administration of the both drugs. Previous in 
vitro studies showed that PPIs could attenuate 
the antiplatelet of clopidogrel.21,22 However, 
this study showed that the potential interaction 
between clopidogrel and PPIs did not give 
clinical implications in patients with ischemic 
stroke. 
Some limitations of this study were 
suspected. Data of duration of the drug use 
were not available; therefore, misclassification 
bias of long exposure of the drug could be 
occurred. Furthermore, data of doses of drug 
use could not be obtained. The doses of drug 
use might influence the clinical implication of 
the drug interaction that happened.  
CONCLUSION
Among patients receiving with clopidogrel 
after ischemic stroke, PPIs exposure  does 
not influence the effect of clopidogrel on 
the risk of recurrent ischemic stroke event. 
Therefore, it can be concluded that there is 
no association between PPIs exposure and the 
risk of recurrent stroke in patients receiving 
clopidogrel. 
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